| GOSS Shares Outstanding History Table | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Below is a table of the GOSS shares outstanding history going back to 2/8/2019:
Also see: GOSS Market Cap History GOSS YTD Return |
GOSS Shares Outstanding History — Gossamer Bio Share Count Over Time
As of 8/8/2026 Gossamer Bio has 6.11 million GOSS shares outstanding. Investors often track the GOSS shares outstanding history to compare shareholder return trends against the change in share count over time.
This page shows GOSS share count trends over time, with 32 historical shares outstanding datapoints presented, dating back to 2/8/2019.
| GOSS Shares Outstanding History Chart | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GOSS Historical Shares Outstanding: +32.16% CAGR 
Mouse over chart for data details
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| GOSS Stock Price Chart |
| About Gossamer Bio Inc |
| Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. Co. is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH). Its product candidate Seralutinib, also known as GB002, is an investigational inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor (CSF1R), and c-KIT inhibitor, being evaluated in a Phase III clinical trial for the treatment of PAH. In contrast to the three classes of marketed vasodilatory therapies for PAH, its seralutinib has the potential to reverse pathological remodeling by addressing mechanisms that underlie PAH. We show 32 historical shares outstanding datapoints in our coverage of GOSS's shares outstanding history. Understanding the changing numbers of GOSS shares outstanding — and comprehending the concept of differing number of shares outstanding in general comparing companies like GOSS versus peers — is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies. Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history. With this page we aim to empower investors researching GOSS by allowing them to research GOSS shares outstanding history as well as any other stock in our coverage universe. |
| GOSS Current Stock Quote |
Quotes delayed 20 minutes  Free GOSS Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| Video: Shares Outstanding Importance | |
|
Video: Shares Outstanding Importance
| GOSS Share Performance |
| Shares Outstanding Peers |
| Gossamer Bio (GOSS) is categorized under the Healthcare sector; to help you further research historical shares outstanding numbers, below are some other companies in the same sector:
GOVX Shares Outstanding History GRAY Shares Outstanding History GRCE Shares Outstanding History GRDN Shares Outstanding History GRDX Shares Outstanding History GRI Shares Outstanding History GRPH Shares Outstanding History GRTS Shares Outstanding History GRTX Shares Outstanding History GTBP Shares Outstanding History More Healthcare companies » |
GOSS Shares Outstanding History | www.SharesOutstandingHistory.com | Copyright © 2017 - 2026, All Rights Reserved
Nothing in SharesOutstandingHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
